The Nordic Baltic Chronic Total Occlusion (CTO) Arrhythmia Study

Condition(s) studied

Investigational drug(s) / intervention(s)

PCI: A loop recorder is implanted i all patients in both study groups to investigate: * Prevalence and severity of cardiac arrhythmias. * Effect on detected arrhythmia, in particular ventricular tachyarrhythmia, of optimal medical therapy vs. coronary revascularization by PCI. * Prevalence and severity of cardiac arrhythmias in CTO-patients with failed PCI. * Indication for prophylactic ICD implantation in CTO-patients treated conservatively or by PCI and after failed PCI. * Relation of arrhythmias to angina pectoris symptoms (CCS class), Quality of life questionnaire results and presence of myocardial reversible perfusion defects by CMRI.

Study summary

In patients with a chronic total coronary occlusion (CTO ), clinically significant arrhythmia seems to be an important and a poorly investigated problem. The arrhythmia prevalence in an all-comer CTO-population is unknown, but in ICD-populations with ischemic heart disease, a CTO may be found in half of patients with life-threatening arrhythmia.The purpose of the CTO-ARRHYTHMIA study, is to investigate the incidence of clinically significant arrhythmias in CTO patients using an implantable loop recorder. Further, the investigators intend to identify predictors for arrhythmias as well as the impact on arrhythmia of optimized pharmacological treatment and revascularization in CTO patients.

Eligibility

Primary outcome measure(s)

• Rate of clinically significant arrhythmias — 1 year
  Rate og clinically significant arrhythmias in PCI versus medically only treated patients by loop recorder (table 1) and in patients with failed PCI.

Trial sites (1)

More Leif Thuesen trials in Denmark